Literature DB >> 9864144

Murine T lymphocytes incapable of producing macrophage inhibitory protein-1 are impaired in causing graft-versus-host disease across a class I but not class II major histocompatibility complex barrier.

J S Serody1, D N Cook, S L Kirby, E Reap, T C Shea, J A Frelinger.   

Abstract

The routine use of bone marrow transplantation is limited by the occurrence of acute and chronic graft-versus-host disease (GVHD). Current approaches to decreasing the occurrence of GVHD after allogeneic transplantation use T-cell depletion, use immunosuppressive agents, or block costimulatory molecule function. The role of proteins in the recruitment of alloreactive lymphocytes has not been well characterized. Chemokines are a large family of proteins that mediate recruitment of mononuclear cells in vitro and in vivo. To investigate the role of T-cell production of the chemokine macrophage inhibitory protein-1 (MIP-1) in the occurrence of GVHD, splenocytes either from wild-type or from MIP-1-/- mice were administered to class I (B6.C-H2(bm1)) and class II disparate mice (B6-C-H2(bm12)). The incidence and severity of GVHD was markedly reduced in bm1 mice receiving splenocytes from MIP-1-/- mice as compared with mice receiving wild-type splenocytes. Bm1 mice receiving MIP-1-/- splenocytes had significantly less weight loss and markedly reduced inflammatory responses in the lung and liver than mice receiving C57BL/6 splenocytes. Bm1 mice receiving MIP-1-/- splenocytes had a markedly decreased production of antichromatin autoantibodies and impaired generation of bm1-specific T lymphocytes versus wild-type mice. However, MIP-1-/- splenocytes easily induced GVHD when administered to bm12 mice. This data show that blockade of chemokine production or function may provide a new approach to the prevention or treatment of GVHD but that chemokines that recruit both CD4(+) and CD8(+) lymphocytes may need to be targeted.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9864144

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  The chemokine, CCL3, and its receptor, CCR1, mediate thoracic radiation-induced pulmonary fibrosis.

Authors:  Xuebin Yang; William Walton; Donald N Cook; Xiaoyang Hua; Stephen Tilley; Christopher A Haskell; Richard Horuk; A William Blackstock; Suzanne L Kirby
Journal:  Am J Respir Cell Mol Biol       Date:  2010-09-24       Impact factor: 6.914

2.  Chemokine receptor CCR5 mediates alloimmune responses in graft-versus-host disease.

Authors:  Lisa A Palmer; George E Sale; John I Balogun; Dan Li; Dan Jones; Jeffrey J Molldrem; Rainer F Storb; Qing Ma
Journal:  Biol Blood Marrow Transplant       Date:  2009-12-16       Impact factor: 5.742

3.  The role of chemokines in mediating graft versus host disease: opportunities for novel therapeutics.

Authors:  Marina G M Castor; Vanessa Pinho; Mauro M Teixeira
Journal:  Front Pharmacol       Date:  2012-02-24       Impact factor: 5.810

4.  Stromal interferon-γ signaling and cross-presentation are required to eliminate antigen-loss variants of B cell lymphomas in mice.

Authors:  Armin Gerbitz; Madhusudhanan Sukumar; Florian Helm; Andrea Wilke; Christian Friese; Cornelia Fahrenwaldt; Frank M Lehmann; Christoph Loddenkemper; Thomas Kammertoens; Josef Mautner; Clemens A Schmitt; Thomas Blankenstein; Georg W Bornkamm
Journal:  PLoS One       Date:  2012-03-30       Impact factor: 3.240

Review 5.  Chemokines in chronic liver allograft dysfunction pathogenesis and potential therapeutic targets.

Authors:  Bin Liu; Jing Li; Lu-Nan Yan
Journal:  Clin Dev Immunol       Date:  2013-12-08

Review 6.  Chemokines as molecular targets for therapeutic intervention.

Authors:  O M Howard; J J Oppenheim; J M Wang
Journal:  J Clin Immunol       Date:  1999-09       Impact factor: 8.317

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.